STOCK TITAN

Zymeworks (NASDAQ: ZYME) insider plans 6,120-share Rule 144 sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Zymeworks Inc. insider Mark Hollywood has filed a Form 144 notice to sell common stock. The filing covers a planned sale of 6,120 shares of common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026, with an indicated aggregate market value of $141,800.40. The class is listed on the Nasdaq, and there were 74,836,534 shares of this class outstanding.

The shares to be sold are tied to equity compensation, as 17,666 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units granted by the issuer. The filer also reported that, during the prior three months, Mark Hollywood sold 8,911 shares of common stock on 01/05/2026 for gross proceeds of $223,638.47. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about Zymeworks’ current or prospective operations.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does ZYME's latest Form 144 filing disclose?

It discloses that Mark Hollywood intends to sell 6,120 shares of Zymeworks Inc. common stock under Rule 144, with an aggregate market value of $141,800.40 and an approximate sale date of 01/12/2026.

How many ZYME shares are outstanding in this Form 144?

The filing states that 74,836,534 shares of Zymeworks Inc. common stock were outstanding for the class of securities referenced in the planned Rule 144 sale.

How were the Zymeworks (ZYME) shares being sold acquired?

The filing notes that 17,666 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units issued by Zymeworks Inc., with the nature of payment described as vesting of an award.

Has this ZYME insider sold shares in the past three months?

Yes. The document reports that Mark Hollywood sold 8,911 shares of Zymeworks common stock on 01/05/2026 for $223,638.47 in gross proceeds during the past three months.

Which broker is handling the planned ZYME share sale in the Form 144?

The planned Rule 144 sale of Zymeworks common stock is listed as being handled by Morgan Stanley Wealth Management Canada, with the securities to be sold on the Nasdaq exchange.

What representation does the seller make in this Zymeworks Form 144?

By signing the notice, the seller represents that they do not know any material adverse information about Zymeworks Inc.’s current or prospective operations that has not been publicly disclosed, consistent with Rule 144 requirements.
Zymeworks

NASDAQ:ZYME

ZYME Rankings

ZYME Latest News

ZYME Latest SEC Filings

ZYME Stock Data

1.70B
71.82M
0.8%
101.5%
9.09%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIDDLETOWN